Researchers define burden of Hepatitis in Democratic Republic of the Congo

October 18, 2017
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.

Hepatitis C virus is a curable infectious disease, but treatment remains unavailable in resource-limited settings like the Democratic Republic of the Congo (DRC). The DRC Ministry of Health asked the University of North Carolina at Chapel Hill (UNC) to help determine the burden of infection and find a way to connect people infected with the virus to treatment. Using laboratory equipment readily available in developing countries, researchers from UNC and Abbott Diagnostics were able to define and map the burden of disease in the DRC. Their findings were published in Clinical Infectious Diseases.

"Many people suffering from hepatitis C remain undiagnosed and untreated, despite the advent of highly effective antiviral medications," said Jonathan Parr, M.D., M.P.H., the study's lead author and a researcher within UNC's Infectious Disease Epidemiology and Ecology Lab. "We used a simple, high throughput testing approach to map hepatitis C infections throughout the DRC. We showed that a single drop of blood collected by fingerprick can be used to identify candidates for treatment and to assess the burden of in resource-limited settings."

The UNC-Abbott team adapted a common hepatitis C virus test for use with small spots of blood dried onto filter paper. The filter papers were then processed using the Abbott m2000 platform, which is widely used to detect HIV in the DRC and other countries. The researchers determined that about 1 percent or between 100,000 and 200,000 adults living in the DRC had hepatitis C.

"We developed a simple, scalable testing algorithm that can be used in the developing world where there are minimal lab capabilities," Parr said. "We repurposed existing infrastructure, proved that the dried blood spot test worked and defined the burden of hepatitis C in the DRC."

Steven Meshnick, M.D., Ph.D., professor of epidemiology and microbiology, and a co-author of the study said, "We've been delighted to help our partners at the Kinshasa School of Public Health and the DRC National AIDS Control Program to strengthen viral diagnosis in the DRC. We now hope to work with them to obtain and roll out therapies."

Explore further: New test IDs genotype of hepatitis C

Related Stories

New test IDs genotype of hepatitis C

June 20, 2013
(HealthDay)—A new test to help doctors identify the genotype of a person's hepatitis C infection has been approved by the U.S. Food and Drug Administration.

Hepatitis C nearly triples in US in 5 years

May 11, 2017
The number of hepatitis C infections have nearly tripled in the United States in the last five years, particularly among people in their 20s, researchers said Thursday.

Around 9 million Europeans are affected by chronic hepatitis B or C

July 26, 2017
An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet ...

Hepatitis C tied to increased risk of Parkinson's

December 24, 2015
The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the December 23, 2015, online issue of Neurology, the medical journal of the American Academy ...

Cases of hepatitis B and C hit 325 million: WHO

April 21, 2017
An estimated 325 million people are living with hepatitis B or C and few are aware of their condition, with death tolls from the viruses rising, the UN said Friday.

Hepatitis C now leading infectious disease killer in U.S.

May 5, 2016
(HealthDay)—The number of hepatitis C-linked deaths in the United States reached a record high in 2014, and the virus now kills more Americans than any other infectious disease, health officials report.

Recommended for you

New cellular approach found to control progression of chronic kidney disease

December 15, 2017
Researchers have demonstrated for the first time that extracellular vesicles - tiny protein-filled structures - isolated from amniotic fluid stem cells (AFSCs) can be used to effectively slow the progression of kidney damage ...

Testing shows differences in efficacy of Zika vaccines after one year

December 15, 2017
(Medical Xpress)—A large team of researchers with members from Harvard Medical School, Walter Reed Army Institute of Research, Bioqual Inc. and MIT has found that the efficacy of the three types of Zika vaccines currently ...

How to regulate fecal microbiota transplants

December 15, 2017
(Medical Xpress)—A small team of researchers at the University of Maryland, some with affiliations to the Veterans Affairs Maryland Health Care System, has written and published a Policy Forum piece in the journal Science ...

Screening could catch a quarter of hip fractures before they happen

December 15, 2017
Community screening for osteoporosis could prevent more than a quarter of hip fractures in older women - according to new research led by the University of East Anglia (UEA).

Urine test developed to test for tuberculosis

December 14, 2017
(Medical Xpress)—An international team of researchers has developed a urine test that can be used to detect tuberculosis (TB) in human patients. In their paper published in Science Translational Medicine, the group describes ...

40 years after first Ebola outbreak, survivors show signs they can stave off new infection

December 14, 2017
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.